Co-promotion of sales and medical affairs percentage.

No definition available.

Name:	mdvn_CoPromotionOfSalesAndMedicalAffairsPercentage
Namespace Prefix:	mdvn_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Maximum Eligible Future Development Milestone Payments Under Collaboration Arrangement

+ References

No definition available.

+ Details

Name:	mdvn_MaximumEligibleFutureDevelopmentMilestonePaymentsUnderCollaborationArrangement
Namespace Prefix:	mdvn_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Maximum Eligible Future Sales Milestone Payments Under Collaboration Arrangement

+ References

No definition available.

+ Details

Name:	mdvn_MaximumEligibleFutureSalesMilestonePaymentsUnderCollaborationArrangement
Namespace Prefix:	mdvn_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Milestone Payments Received To Date Under Collaboration Arrangement

+ References

No definition available.

+ Details

Name:	mdvn_MilestonePaymentsReceivedToDateUnderCollaborationArrangement
Namespace Prefix:	mdvn_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Milestone Related Payments To Licensor

+ References

No definition available.

+ Details

Name:	mdvn_MilestoneRelatedPaymentsToLicensor
Namespace Prefix:	mdvn_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Percentage of Development Milestone Payments To Licensor

+ References

No definition available.

+ Details

Name:	mdvn_PercentageOfDevelopmentMilestonePaymentsToLicensor
Namespace Prefix:	mdvn_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Percentage Of Net Sales Under Collaboration Agreement

+ References

No definition available.

+ Details

Name:	mdvn_PercentageOfNetSalesUnderCollaborationAgreement
Namespace Prefix:	mdvn_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Percentage of sales milestone payments.

+ References

No definition available.

+ Details

Name:	mdvn_PercentageOfSalesMilestonePayments
Namespace Prefix:	mdvn_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Share Of Substantive Milestones To Licensor

+ References

No definition available.

+ Details

Name:	mdvn_ShareOfSubstantiveMilestonesToLicensor
Namespace Prefix:	mdvn_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Share Of U S Development And Commercialization Cost Under Collaboration Arrangement

+ References

No definition available.

+ Details

Name:	mdvn_ShareOfUSDevelopmentAndCommercializationCostUnderCollaborationArrangement
Namespace Prefix:	mdvn_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Share Percentage Of Development And Commercialization Cost Under Former Collaboration

+ References

No definition available.

+ Details

Name:	mdvn_SharePercentageOfDevelopmentAndCommercializationCostUnderFormerCollaboration
Namespace Prefix:	mdvn_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Substantive Milestones Received

+ References

No definition available.

+ Details

Name:	mdvn_SubstantiveMilestonesReceived
Namespace Prefix:	mdvn_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of deferred revenue recognized for transactions arising during the current reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an Entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=6600647&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name:	us-gaap_DeferredRevenueAdditions
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_DeferredRevenueArrangementLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

Collaboration Agreements (Narrative) (Detail) (USD $) In Millions, unless otherwise specified	3 Months Ended	9 Months Ended	3 Months Ended								9 Months Ended	3 Months Ended	9 Months Ended	3 Months Ended
	Sep. 30, 2012	Sep. 30, 2012	Dec. 31, 2008 Up-Front And Milestone Payments [Member] Pfizer [Member]	Sep. 30, 2012 Up-Front And Milestone Payments [Member] Astellas [Member]	Sep. 30, 2012 Development Cost Sharing Payments [Member] Pfizer [Member] Collaborative Arrangement [Member]	Dec. 31, 2008 Development Cost Sharing Payments [Member] Pfizer [Member] Collaborative Arrangement [Member]	Sep. 30, 2012 Commercial Cost Sharing Payments [Member] Pfizer [Member] Collaborative Arrangement [Member]	Dec. 31, 2008 Commercial Cost Sharing Payments [Member] Pfizer [Member] Collaborative Arrangement [Member]	Sep. 30, 2012 Development Milestone Payments [Member]	Sep. 30, 2012 Development Milestone Payments [Member] Astellas [Member]	Sep. 30, 2012 Development Milestone Payments [Member] Astellas [Member]	Sep. 30, 2012 Sales Milestone Payments [Member] Astellas [Member]	Sep. 30, 2012 Sales Milestone Payments [Member] Astellas [Member]	Sep. 30, 2012 UCLA's [Member]
Deferred Revenue Arrangement [Line Items]
Co-promotion of sales and medical affairs percentage		50.00%
Non-refundable up-front cash payment			$ 225.0	$ 110.0
Eligible to receive milestone payments										335.0
Maximum eligible future sales milestone payments under collaboration arrangement												320.0
Deferred revenue additions related to development milestones											58.0
Percentage share of development milestone payments											10.00%
Percentage of sales milestone payments		10.00%											10.00%
Milestone and development milestone sharing payments	6.5													2.0
Development milestone payments														4.5
Development milestone payments earned									$ 45.0
Share percentage of developing and commercializing dimebon						60.00%		40.00%
Share percentage of developing and commercializing					50.00%		50.00%
Collaboration revenue percentage compared to U.S. XTANDI net sales	50.00%	50.00%